MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-10-2026
Medpace Holdings Interest Expense 2011-2026 | MEDP
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Medpace Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.34 M | 4.06 M | -655 K | 7.07 M | 3.34 M | 1.18 M | -863 K | 1.06 M | -354 K | -423 K | -1.13 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.07 M | -5.34 M | 722 K |
Quarterly Interest Expense Medpace Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -489 K | -2.88 M | -1.82 M | - | -1.02 M | -133 K | 4.59 M | - | -1.6 M | -1.28 M | 687 K | - | 5.65 M | 2.31 M | 1.07 M | - | 1.06 M | 265 K | 924 K | - | 584 K | 239 K | 617 K | - | -273 K | -19 K | -282 K | - | 482 K | 478 K | -153 K | - | -145 K | -125 K | -372 K | - | -378 K | -6 K | -935 K | - | 50 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.65 M | -2.88 M | 229 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Anixa Biosciences
ANIX
|
500 K | $ 2.89 | -2.36 % | $ 93.8 K |  USA |
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
81 M | $ 118.67 | 0.46 % | $ 36.1 B | USA |
 |
Celcuity
CELC
|
2.11 M | $ 109.39 | 1.0 % | $ 4.32 B | USA |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Castle Biosciences
CSTL
|
1 K | $ 27.81 | -0.64 % | $ 772 M | USA |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 177.9 | -0.41 % | $ 8.82 B | USA |
 |
Aspira Women's Health
AWH
|
106 K | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Fulgent Genetics
FLGT
|
561 K | $ 14.03 | -1.23 % | $ 424 M | USA |
|
Biodesix
BDSX
|
8.26 M | $ 15.96 | 1.3 % | $ 2.07 B | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
-10.1 M | $ 1.1 | -3.49 % | $ 1.4 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 208.55 | -0.82 % | $ 23.1 B | USA |
 |
Danaher Corporation
DHR
|
-222 M | $ 202.93 | -1.44 % | $ 145 B | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | $ 103.39 | 0.04 % | $ 19.5 B | USA |
 |
Bioventus
BVS
|
1.29 M | $ 8.85 | 0.91 % | $ 554 M | USA |
 |
DarioHealth Corp.
DRIO
|
-31 K | $ 10.5 | -2.33 % | $ 298 M |  Israel |
 |
DexCom
DXCM
|
177 M | $ 72.97 | -1.1 % | $ 28.5 B | USA |
 |
QIAGEN N.V.
QGEN
|
-739 K | - | - | $ 10.6 B |  Niderland |
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 24.2 | -3.82 % | $ 254 M | China |
 |
CareDx, Inc
CDNA
|
524 K | $ 18.66 | -0.45 % | $ 994 M | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 108.73 | 0.42 % | $ 8.97 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
29.8 M | $ 635.4 | -0.2 % | $ 51.1 B | USA |
 |
Illumina
ILMN
|
-292 M | $ 130.82 | -1.55 % | $ 20.8 B | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M | Israel |
 |
Guardant Health
GH
|
-10.5 M | $ 93.48 | 1.35 % | $ 11.7 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 283.3 | -1.03 % | $ 23.6 B | USA |
 |
IQVIA Holdings
IQV
|
729 M | $ 174.31 | 0.02 % | $ 30 B | USA |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 78.0 | 2.23 % | $ 5.26 B | USA |
 |
Co-Diagnostics
CODX
|
106 K | - | - | $ 79.8 M | USA |
 |
Mettler-Toledo International
MTD
|
68.5 M | $ 1 317.07 | -0.45 % | $ 27.1 B |  Schweiz |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
Myriad Genetics
MYGN
|
800 K | $ 5.26 | 4.99 % | $ 487 M | USA |
 |
NeoGenomics
NEO
|
296 K | $ 9.5 | - | $ 1.22 B | USA |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
9.32 M | $ 208.69 | 4.26 % | $ 20.5 B | USA |
 |
Pacific Biosciences of California
PACB
|
14.8 M | $ 1.54 | -4.94 % | $ 462 M | USA |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 11.01 | -1.3 % | $ 2.39 B | USA |
 |
Precipio
PRPO
|
-1 K | $ 24.5 | -0.73 % | $ 31.8 M | USA |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |